To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 14, 2018

Today's Rundown

Featured Story

SVB buys Leerink for $280M, boosting its life sciences business

Silicon Valley Bank parent SVB is buying Leerink to create a new company with a "complete capital markets offering."

Top Stories

Preclinical biotech Synthorx wants a $100M IPO

Moderna will be getting all the headlines for its monster $500 million IPO attempt this week, but that shouldn’t overshadow the major $100 million IPO that early-stage Synthorx has just announced, and what this says about the biotech market.

Eli Lilly files for FDA approval of migraine drug lasmiditan

Eli Lilly has filed for FDA approval of migraine drug lasmiditan. The Big Pharma is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug clears headache pain in two hours in some patients.

[Sponsored] Global Life Science Services Platform Unites Under New Name, EVERSANA

EVERSANA delivers a fully-integrated service portfolio to help life science leaders create value for key constituents across the product lifecycle.

Google to retake DeepMind’s AI healthcare unit, as it moves toward a cohesive strategy

Days after poaching a health system executive to pull together its disparate healthcare ventures, Google moved to reabsorb DeepMind’s health business, including those behind its mobile app for doctors and nurses.

[Sponsored] Mining Real-World Data With Cutting-Edge Analytical Tools

In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In those days, there were no scientific tools to guide prospectors in their search. Sites of previous finds were the starting point for what became, for many, a shattered dream.

Bayer VP Alan Westwood to lead antimicrobial firm Matoke Pharma

Former Bayer VP Alan Westwood has taken the reins of British antimicrobial biotech Matoke Pharma.

Celgene expands Dragonfly NK cells pact to the tune of $50M

Celgene is doubling down on its cancer immunotherapy pact with Dragonfly Therapeutics, paying $50 million upfront for access to four more natural killer (NK) cell-based programs.

Enrollment Showcase

BioBasics Dec. 5-6

BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today!

Resources

[Whitepaper] Migraine Treatment and Calcitonin Gene-Related Peptide Inhibitors: Real-World EHR Case Study

New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management

[Whitepaper] The Future of Cell & Gene Therapy

What does data tell us about the future of cell & gene therapy?

[Whitepaper] Choosing the Best Sterile Dosage Form for Your Clinical Supply Needs

Download the whitepaper to learn more.

[Whitepaper] Why Life Sciences Companies Leverage Managed Regulated Infrastructures

Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms.

[Infographic] Accelerate Your Early Drug Delivery Journey

In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion.

[Workshop] Smart Drug Development & Design from Candidate to Phase I

Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development.

[Executive Summary] From Candidate to Clinic

What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program.

[eBook] 2018 State of Technology in Clinical Research

Discover what over 800 of your peers think about technology's impact on clinical trial operations.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

[eLearning] BIOAVAILABILITY 101

Develop a basic understanding of principles and concepts of bioavailability of oral drugs.

Events

.